FCA-BExo composite material as well as preparation method and application thereof
By preparing the fCA-BExo nano-exosome complex formed by co-culturing Co, Al layered nanosheets and stem cells, the problem of osteogenic differentiation disorder and ROS-driven immune imbalance in osteoporosis treatment was solved, and systematic remodeling of the bone metabolism microenvironment and effective treatment of osteoporosis were achieved.
Patent Information
- Application Number
- CN202510835300.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-06-20
- Publication Date
- 2025-08-29
AI Technical Summary
Existing osteoporosis treatment methods cannot simultaneously solve the problem of osteogenic differentiation disorders in the aging microenvironment and ROS-driven immune imbalance. Traditional stem cell therapy has bottlenecks such as insufficient ROS clearance efficiency, limited delivery of active ingredients, and difficulty in large-scale preparation.
Laminated nanosheets were prepared using Co and Al biofriendly elements, co-cultured with stem cells, and formed a fCA-BExo nano-exosome complex. ROS was efficiently removed through electron vacancies on the surface of nanomaterials, and the NF-κB inflammation pathway was synchronized to promote BMP2 expression and osteogenic differentiation.
It realizes systematic remodeling of the bone metabolism microenvironment, efficiently clears ROS, inhibits inflammatory response, promotes osteogenic differentiation of aging stem cells, delays bone absorption and promotes mineralized bone formation, providing a treatment plan that is both accurate and safe.
Smart Images

Figure CN120549871A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biomedical materials, and in particular to an fCA-BExo composite material and a preparation method and application thereof. Background Art
[0002] Osteoporosis (OP) is a systemic skeletal disease characterized by an imbalance in bone metabolism, characterized by increased bone resorption and decreased bone formation, leading to decreased bone mass, deterioration of bone microarchitecture, and a significantly increased risk of fracture. Aging is a major contributing factor. With aging, the osteogenic differentiation capacity of bone marrow mesenchymal stem cells (BMSCs) gradually declines. Excessive accumulation of reactive oxygen species (ROS) further exacerbates oxidative stress, triggering macrophage polarization toward a pro-inflammatory M1 phenotype, activating inflammatory signaling pathways, promoting osteoclast differentiation, and inhibiting bone repair. This pathological process creates a vicious cycle of "oxidative damage-inflammation-bone resorption," necessitating treatment that addresses the dual goals of promoting bone repair and inhibiting abnormal immune cell activation.
[0003] Clinically, bisphosphonates are mainly used to inhibit osteoclast activity, estrogen replacement to regulate bone metabolism, or glucocorticoids to control inflammation in the short term, but these schemes have significant defects. Long-term use of bisphosphonates may cause mandibular osteonecrosis and atypical fractures, and cannot reverse bone formation defects; estrogen therapy increases the risk of breast cancer and thrombosis, while glucocorticoids exacerbate bone loss and lead to metabolic disorders. More importantly, existing therapies mostly target a single pathological link and cannot simultaneously solve the problems of osteoblast differentiation disorders and ROS-driven immune imbalance in the aging microenvironment. For example, although bisphosphonates can inhibit osteoclasts, they have no effect on the osteogenic differentiation of BMSCs; although anti-inflammatory drugs can relieve local inflammation, they cannot clear ROS or repair bone matrix. Therefore, there is an urgent need to develop a comprehensive therapy with "antioxidant-anti-inflammatory-promoting bone formation" functions to break the vicious cycle of osteoporosis.
[0004] In recent years, mesenchymal stem cell-derived exosomes (BMSC-Exo) have demonstrated unique advantages in the treatment of osteoporosis due to their multipotential differentiation-promoting and immunomodulatory properties. Studies have shown that BMSC-Exo can reshape the bone metabolic microenvironment through targeted delivery of functional molecules. For example, Alberto González-González's team found that exosomes containing Smurf1 knockout significantly upregulated alkaline phosphatase (ALP) activity and inhibited osteoclast differentiation by regulating the RANKL / OPG ratio, achieving a dual regulatory effect of "anti-bone resorption and promoting bone formation." Yongzhi Cui et al. further innovated the delivery strategy, using engineered exosomes to deliver siShn3, effectively inhibiting osteoclastogenesis and promoting angiogenesis and bone mineralization, providing a new paradigm for repairing the osteoporosis microenvironment. However, traditional stem cell therapies still face bottlenecks such as insufficient ROS scavenging efficiency, limited delivery of active ingredients, and difficulties in scalable production, resulting in limited ability to regulate immune homeostasis.
[0005] New two-dimensional layered nanomaterials have attracted significant attention in the biomedical field due to their unique physicochemical properties. These materials are composed of layers of positively charged M²⁺-M³⁺ metal cations (such as Mg²⁺ / Al³⁺ and Zn²⁺ / Fe³⁺) stacked with interlayer OH⁻ anions through electrostatic interactions, forming monolayer or few-layer structures only 1-2 nanometers thick. Their unique two-dimensional morphology endows these materials with three remarkable properties: First, the ultrathin layered structure yields a surface area of hundreds of m² / g, exposing abundant surface metal active sites and edge defects; second, the sustained release of interlayer ions can regulate the homeostasis of the biological microenvironment by regulating the release of metal cations; more importantly, the densely distributed catalytic active sites on the surface of the two-dimensional nanosheets effectively mediate electron transfer, efficiently converting excess reactive oxygen species (ROS) in pathological microenvironments into harmless substances such as H₂O, successfully compensating for the inefficient ROS scavenging of stem cell exosomes. Summary of the Invention
[0006] In light of this, the present invention aims to develop a multi-target synergistic nanosheet-exosome composite (fCA-BExo) for the treatment of osteoporosis, addressing the vicious cycle of "oxidative damage-inflammation-bone resorption." Here, we innovatively utilize biofriendly elements, Co and Al, to replace the precious and heavy metals previously developed by researchers, achieving excellent biocompatibility. Furthermore, the Co-ion-containing layered nanosheets can induce mesenchymal stem cells to secrete more exosomes and increase the content of bone morphogenetic protein (BMP2) in these exosomes. Furthermore, the self-assembly ability of fCA-BExo integrates the osteogenic differentiation potential of stem cell exosomes with their bone marrow homing effect, thereby enhancing the nanosheet's biosafety and targeting the bone marrow microenvironment.
[0007] The technical solution adopted in the present invention is:
[0008] In a first aspect, the present invention provides an fCA-BExo nano-exosome complex material.
[0009] In response to the challenges faced by traditional treatments, this study proposes a synergistic treatment strategy based on layered nanomaterials and exosomes. By co-culturing cobalt aluminum layered double hydroxide (f-CoAl(OH)) nanosheets with stem cells, the atomic-level layered structure of f-CoAl(OH) nanosheets is utilized to release Co 2+ By mimicking hypoxia signals, the nanomaterial significantly enhances exosome secretion efficiency and BMP2 expression. Furthermore, the abundant electron vacancies on its surface endow it with efficient ROS scavenging capabilities, simultaneously alleviating oxidative stress and blocking the NF-κB inflammatory pathway. This exosome-nanocomplex system (fCA-BExo) transcends the limitations of monotherapy by achieving systemic remodeling of the bone metabolic microenvironment through a multi-dimensional synergistic mechanism of "antioxidant-immunomodulatory-osteogenesis promotion." This strategy not only preserves the natural bioactivity of stem cells but also optimizes therapeutic efficacy through material-cell interface engineering, providing an innovative, precise and safe approach for the clinical translation of osteoporosis.
[0010] The nanosheet-exosome composite was synthesized via the following steps: First, a cobalt substrate and an aluminum substrate were heated and stirred in the presence of formamide, an activating agent, to form a novel two-dimensional layered nanostructure, f-CoAl(OH). Subsequently, f-CoAl(OH) was co-incubated with mesenchymal stem cells to induce exosome production. After 48 days of induction, fCA-BExo was extracted and purified.
[0011] The nanosheet-exosome composite material provided by the present invention is primarily formed through stem cell uptake of the nanosheets and subsequent exocytosis. Not only does it possess the high biocompatibility and targeting properties of exosomes, but the layered nanosheets and BMP2 released within the bone marrow microenvironment can simultaneously effectively remove ROS, alleviate inflammatory responses, and promote osteogenic differentiation in aging stem cells.
[0012] In a second aspect, another object of the present invention is to provide a method for preparing the aforementioned fCA-BExo nanosheet-exosome composite material. 218.275 mg of cobalt nitrate hexahydrate (Co(NO₃)₂·6H₂O) was dissolved in 20 mL of deionized water to form a red solution, Solution A. Simultaneously, 93.783 mg of aluminum nitrate nonahydrate (Al(NO₃)₃·9H₂O) was dissolved in 20 mL of deionized water to form a transparent solution, Solution B. Under continuous vigorous stirring, Solutions A and B were simultaneously added dropwise over 10 minutes to 20 mL of a 23% formamide solution preheated to 85°C, maintaining the pH of the reaction system at 10. With magnetic stirring (200 rpm), the mixture gradually turned from clear to a light red, turbid suspension. After the reaction, the precipitate was collected by centrifugation (8000 rpm, 10 minutes) and washed twice with ethanol and deionized water to remove impurities, successfully preparing f-CA(OH) nanosheets. During this process, the preheating of formamide and the precise control of pH jointly regulate the crystallization behavior of the nanosheets, while the slow synchronous dripping strategy of the two solutions ensures the uniform co-precipitation of metal ions, thereby forming a product with a layered structure.
[0013] Then, f-CA(OH) was co-cultured with BMSCs to induce the production of fCA-BExo. BMSCs were cultured at a rate of 5×10 6 Cells were seeded at a density of 100 μg / mL in a culture flask. When the cell confluence reached approximately 60%, complete culture medium containing 0.1 mg / mL f-CA(OH) nanosheets was added for 24 hours. The culture medium was then replaced with serum-free medium containing the same concentration of f-CA(OH) and incubated for another 24 hours (at which point the cell confluence exceeded 90%). The culture supernatant was collected and subjected to a series of gradient centrifugations: first at 300 × g for 10 minutes to remove cell debris, then at 2000 × g for 30 minutes to remove large particles, and finally to ultracentrifugation (100,000 × g, 4°C, 120 minutes) to enrich exosomes. The resulting pellet was resuspended in PBS to obtain fCA-BExo.
[0014] In a third aspect, the present invention aims to provide the use of the fCA-BExo complex as a highly efficient ROS scavenging material and osteogenic induction material.
[0015] In a fourth aspect, the present invention aims to provide a use of the fCA-BExo complex in the preparation of an OP diagnostic and therapeutic agent.
[0016] Furthermore, the fCA-BExo complex was dispersed in PBS or physiological saline, and the administration concentration was 200 μg / mL.
[0017] Compared with the existing technology, the beneficial effects of this experiment are:
[0018] The two-dimensional layered nanomaterial, through its superior structural advantages, achieves efficient catalytic activity, decomposing ROS to produce water and oxygen, effectively suppressing inflammation while inducing the formation of fCA-BExo complexes within BMSCs. By utilizing exosomes to form the complex, the biosafety and targeting properties of the nanomaterial are further optimized. Furthermore, the osteoinductive capacity of the exosomes complements the osteogenic differentiation potential of senescent cells, which is lacking in the nanosheets. This plays a crucial role in delaying bone resorption and promoting mineralized bone formation in the pathological process of osteoporosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] In order to more clearly illustrate the technical solutions of the present invention or the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art.
[0020] Figure 1 Schematic diagram of the synthesis steps and therapeutic principle of the fCA-BExo complex of the present invention;
[0021] Figure 2A Transmission electron microscope image of f-CoAl(OH) in Test Example 1;
[0022] Figure 2B This is a scanning electron microscope image of f-CoAl(OH) in Test Example 1;
[0023] Figure 3 This is the elemental mapping spectrum of f-CoAl(OH) in Test Example 1;
[0024] Figure 4A This is the high-resolution XPS spectrum of f-CoAl(OH) in Test Example 1;
[0025] Figure 4B Detailed peaks of Co 2p and Al 3p in the high-resolution XPS spectrum of f-CoAl(OH) in Test Example 1;
[0026] Figure 5 Transmission electron microscope image of fCA-BExo in Test Example 1;
[0027] Figure 6 Elemental mapping of fCA-BExo in test case 1;
[0028] Figure 7 is the particle size diagram of fCA-BExo in Test Example 1;
[0029] Figure 8 Zeta potential diagrams of f-CoAl(OH), ordinary exosomes (Exo), and fCA-BExo in test example 1;
[0030] Figure 9 This is the biosafety verification of fCA-BExo in Experimental Example 1;
[0031] Figure 10 This is the live / dead staining assay for fCA-BExo cells in Experimental Example 1;
[0032] Figure 11A The confocal microscopy images show the internalization of fCA-BExo into cells at different time periods in Experiment 1.
[0033] Figure 11B Quantify the internalization of fCA-BExo at different time points by flow cytometry in Experimental Example 1;
[0034] Figure 12 ROS staining analysis of the ROS scavenging ability of f-CoAl(OH) in Experimental Example 1;
[0035] Figure 13 Flow cytometry analysis of the inhibition of immune activation by f-CoAl(OH), Exo, and fCA-BExo in Experimental Example 1;
[0036] Figure 14 Alkaline phosphatase staining (ALP staining) was used to evaluate the ability of f-CoAl(OH), Exo, and fCA-BExo to promote early osteogenic differentiation in Experimental Example 1;
[0037] Figure 15 Alizarin Red S staining (ARS staining) was used to evaluate the ability of f-CoAl(OH), Exo, and fCA-BExo to promote late mineralization in Experimental Example 1;
[0038] Figure 16 Micro-CT was used to evaluate the degree of osteoporosis in mice in Experimental Example 2;
[0039] Figure 17 are the Micro-CT-related osteoporosis index parameters in Experimental Example 2;
[0040] Figure 18 HE staining was used to evaluate the pathological changes of osteoporosis in Experimental Example 2;
[0041] Figure 19 TRAP staining was used to evaluate the number of osteoclasts in the bone marrow cavity in Experimental Example 2;
[0042] Figure 20 Safranin fast green staining was used to evaluate cartilage and bone matrix formation in Experimental Example 2;
[0043] Figure 21 Masson staining was used to evaluate collagen secretion and mineralization area in Experimental Example 2. DETAILED DESCRIPTION
[0044] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below with reference to specific embodiments.
[0045] The sources of reagents and instruments involved in the following examples, test examples and experimental examples are as follows:
[0046] Cobalt nitrate hexahydrate (Co(NO₃)₂·6H₂O), aluminum nitrate nonahydrate (Al(NO₃)₃·9H₂O), and formamide were purchased from Aladdin Reagent (Shanghai) Co., Ltd. First-generation bone marrow mesenchymal stem cells (BMSCs) were extracted from the bone marrow contents of C57BL / 6 mice. RAW 264.7 cells were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences. Penicillin, streptomycin, fetal bovine serum, and DMEM high-glucose medium were purchased from Gibco (USA). CCK-8 assay kit, live / dead cell staining kit, alkaline phosphatase staining kit, and Alizarin Red S dye were purchased from Shanghai Biyuntian Biotechnology Co., Ltd.; PBS buffer was purchased from Shanghai Yuanmu Biotechnology Co., Ltd.; 4% chloral hydrate was purchased from Sinopharm Chemical Reagent Co., Ltd.; and decalcification solution was purchased from Shanghai Ruji Biotechnology Development Co., Ltd. All other test materials were AR-grade test materials purchased from Sinopharm. Deionized water was used in this experiment.
[0047] An FD-1C-50 vacuum freeze dryer was purchased from Beijing Boyikang Experimental Instrument Co., Ltd.; a 78-1 magnetic heating stirrer was purchased from Suzhou Well Laboratory Supplies Co., Ltd.; a constant temperature water bath was purchased from Shanghai Yarong Biochemical Instrument Factory; an AB265-S electronic analytical balance was purchased from METTLER, Switzerland; a Teneo scanning electron microscope was purchased from FEI, USA; a transmission electron microscope was purchased from FEI, USA; an X-ray derivative was purchased from Rigaku Co., Ltd., Japan; a collector-type constant temperature heating magnetic stirrer was purchased from Tianjin Huaxin Instrument Co., Ltd.; an H1850 high-speed centrifuge was purchased from Hunan Xiangyi Laboratory Instrument Development Co., Ltd.; a high-speed refrigerated centrifuge was purchased from Hetlich Scientific Instruments, Germany; a 380ZLS dynamic light scattering particle size analyzer was purchased from NICOMP, USA; a UV-3100PC ultraviolet-visible spectrophotometer was purchased from Shanghai Meipuda Instrument Co., Ltd.; a FL4600 fluorescence spectrophotometer was purchased from Shimadzu, Japan; and an inverted optical microscope was purchased from Olympus, Japan. The optical microscope was purchased from Leica, Germany; the 3111 cell culture incubator was purchased from Thermo Fisher Scientific, USA; the surgical instrument kit was purchased from the Animal Center of Xuzhou Medical University; the paraffin embedding machine and paraffin section machine were purchased from the Pathology Center of Xuzhou Medical University; and the digital section scanning microscope was purchased from the Anatomy Laboratory of Xuzhou Medical University.
[0048] Example 1 Preparation of fCA-BExo complex
[0049] Step S1, synthesis of f-CA(OH). 218.275 mg of cobalt nitrate hexahydrate (Co(NO₃)₂·6H₂O) was dissolved in 20 mL of deionized water to form a red solution, Solution A. Simultaneously, 93.783 mg of aluminum nitrate nonahydrate (Al(NO₃)₃·9H₂O) was dissolved in 20 mL of deionized water to form a transparent solution, Solution B. Under continuous vigorous stirring, Solutions A and B were simultaneously added dropwise over 10 minutes to 20 mL of 23% formamide solution preheated to 85°C, maintaining the pH of the reaction system at 10. With magnetic stirring (200 rpm), the mixture gradually turned from clear to a light red, turbid suspension. After the reaction, the precipitate was collected by centrifugation (8000 rpm, 10 minutes) and washed twice with ethanol and deionized water to remove impurities, successfully preparing f-CA(OH) nanosheets.
[0050] Step S2, induction of fCA-BExo. Then, f-CA(OH) was co-cultured with BMSC to induce the production of fCA-BExo. BMSC were cultured at 5×10 6 Cells were seeded into culture flasks at a density of 100 cells / mL. When the cell confluence reached approximately 60%, complete culture medium containing 0.1 mg / mL f-CA(OH) nanosheets was added for 24 hours. The medium was then replaced with serum-free medium containing the same concentration of f-CA(OH) and incubated for another 24 hours (at which point the cell confluence exceeded 90%).
[0051] Step S3: Extraction of fCA-BExo. The culture supernatant was collected and subjected to a series of gradient centrifugation steps: first, at 300 × g for 10 minutes to remove cellular debris, then at 2000 × g for 30 minutes to remove large particles, and finally, to ultracentrifugation (100,000 × g, 4°C, 120 minutes) to enrich exosomes. The resulting pellet was resuspended in PBS to obtain fCA-BExo.
[0052] Test Example 1 Characterization of fCA-BExo Complex and Its Intermediate f-CoAl(OH)
[0053] like Figure 2A , Transmission electron microscopy and scanning electron microscopy images of f-CoAl(OH) in 2B, with scale bars of 50 nm and 100 nm, confirm the main two-dimensional structure of f-CoAl(OH).
[0054] like Figure 3 The element mapping spectrum of f-CoAl(OH) in the sample is 50 nm, and the scale is 50 nm, which confirms that the main elements in f-CoAl(OH) are Co, Al, and O.
[0055] like Figure 4A , the high-resolution XPS spectrum of f-CoAl(OH) in 4B describes the chemical states of Co 2p and Al 3p in detail.
[0056] like Figure 5 Transmission electron microscopy image of fCA-BExo in (scale bar = 50 nm), confirming the successful induction of fCA-Exo.
[0057] like Figure 6 The elemental mapping spectrum of fCA-BExo in the membrane is 50 nm, which confirms that in addition to Co and Al, the main elements in fCA-BExo also contain N, O, C, and P that are unique to the membrane structure.
[0058] like Figure 7 The particle size diagram of fCA-BExo in Figure 3 shows that the induced fCA-BExo particle size is approximately 120-150 nm.
[0059] like Figure 8 The zeta potential diagrams of f-CoAl(OH), ordinary exosomes (Exo), and fCA-BExo in Figure 3 show that the zeta potential of the induced complex is closer to that of Exo.
[0060] Experimental Example 1 Testing of the safety and biocompatibility of fCA-BExo complex
[0061] 1.1 Safety testing of the fCA-BExo complex
[0062] In this experiment, fCA-BExo composite material solutions with different concentrations (0.1 mg / mL, 0.2 mg / mL, 0.3 mg / mL, 0.4 mg / mL, 0.5 mg / mL, 0.6 mg / mL, 0.7 mg / mL, 0.8 mg / mL, 0.9 mg / mL, 1.0 mg / mL) were prepared and added to BMSCs and RAW 264.7 cells to simulate the stem cells and monocytes present in the bone marrow microenvironment to examine their safety.
[0063] At a concentration of 0.1 mg / mL, the survival rates of both cell lines were above 95%, and as the concentration continued to increase, the biosafety decreased. Therefore, the reasonable drug concentration would be controlled at 0.1 mg / mL. Figure 9 Then, using live / dead cell assay, it was found that the drug had almost no effect on normal cell activity at 0.1 mg / mL. Figure 10 , scale bar is 50 μm. The good safety of this material is confirmed.
[0064] 1.2 Biocompatibility testing of fCA-BExo complex
[0065] Subsequently, we used the cellular uptake of the fCA-BExo composite at different administration times to evaluate its biocompatibility. First, we labeled the fCA-BExo composite with the fluorescent marker FITC and added it to BMSCs at different time periods (0 min, 10 min, 30 min, 2 h, and 3 h) before the start of the test. Microscopic observation showed that the fCA-BExo composite was rapidly internalized within 30 minutes and stabilized after 2 hours. Figure 11A , scale bar is 10 μm. We then collected cells from the culture dish and used flow cytometry to evaluate the changes in intracellular fluorescence intensity at different time periods, such as Figure 11B . This further confirmed the good biocompatibility of the fCA-BExo complex.
[0066] 1.3 ROS scavenging ability of f-CoAl(OH)
[0067] First, we pretreated RAW 264.7 cells with lipopolysaccharide (LPS) to simulate in vitro OP bone marrow inflammation, and then added f-CoAl (OH) for co-culture for 12 hours. After 12 hours, ROS staining kit was used for staining observation, as shown in Figure 2. Figure 12 , the scale bar is 200 μm. The ROS fluorescence intensity in the LPS pretreatment group was significantly enhanced compared with the blank control group. Meanwhile, the addition of f-CoAl(OH) significantly reduced the ROS content in the cells.
[0068] 1.4 Ability of f-CoAl(OH) and fCA-BExo to inhibit immune activation response
[0069] At the same time, flow cytometry will measure f-CoAl (OH) and fCA-BExo to see if they can suppress the cascade activation of the immune system by clearing ROS, such as Figure 13 Immune cells were significantly activated after LPS treatment, but immune activation was inhibited after f-CoAl(OH) treatment, and the inhibitory effect of fCA-BExo was more significant.
[0070] 1.5 fCA-BExo induces early differentiation of senescent stem cells
[0071] Bone marrow mesenchymal stem cells (BMSCs) were seeded at a density of 5 × 105 cells per well in 6-well plates. When the cells reached approximately 70% confluency, the culture medium was replaced with osteogenic induction medium (containing high-glucose DMEM, 10% fetal bovine serum, 100 nM dexamethasone, 10 mM sodium β-glycerophosphate, 50 μM ascorbic acid, and the corresponding treatment conditions). Fresh induction medium was replaced every 2 days for a total of 14 days.
[0072] Alkaline phosphatase (ALP) staining was performed 7 days after osteogenic induction. The culture medium was discarded, and the cells were washed three times with pre-cooled PBS, followed by fixation with 4% paraformaldehyde at room temperature for 15 minutes. ALP staining working solution was prepared according to the kit instructions, and the cells were covered and incubated at 37°C for 30 minutes. After the reaction was terminated, the cells were rinsed three times with distilled water and the formation of blue-purple precipitate was observed under an inverted microscope (Olympus IX73, Japan). Figure 14 f-CoAl(OH) induces low osteogenesis efficiency, while fCA-BExo significantly improves early osteogenic differentiation efficiency.
[0073] 1.6 fCA-BExo induces late mineral deposition in aging stem cells
[0074] After 14 days of osteogenic induction, Alizarin Red S (ARS) mineralized nodules were stained. The culture medium was discarded, the cells were washed three times with PBS, and 2% Alizarin Red S solution (pH 4.2) was added to cover the cell layer. The cells were stained at 37°C for 20 minutes. Nonspecific staining was removed by repeated washing with distilled water (until no red dye was dissolved in the washing solution). After drying at room temperature, the formation of red mineralized nodules was observed using an inverted microscope (Olympus IX73, Japan). Figure 15 Scale bar: 100 μm. Mineralized nodules were not obvious in the f-CoAl(OH) group, but were significantly increased in the fCA-BExo group, indicating a significant late osteogenesis effect.
[0075] Experimental Example 2: fCA-Exo improves osteoporosis in animal models
[0076] 2.1 Preparation of osteoporosis mouse model
[0077] Following the classic modeling method for postmenopausal osteoporosis established by Turner RT et al., an osteoporosis mouse model was established by bilateral ovariectomy. Eight-week-old female C57BL / 6 mice were fasted for 6 hours before surgery and anesthetized with 2% isoflurane inhalation. The mice were immobilized in the prone position. The hair on the lumbar and back was shaved, and the surgical area was disinfected with iodine. A longitudinal incision (approximately 0.8 cm) was made 1 cm below the costal arch on both sides of the spine. The muscle layer was bluntly dissected to expose the ovaries and surrounding adipose tissue. After tubal ligation, both ovaries were completely removed, and the muscle and skin were sutured layer by layer. In the sham-operated group, only the ovaries were exposed and sutured in situ, without undergoing resection. Analgesia was maintained with subcutaneous injections of 5 mg / kg carprofen for 3 consecutive days postoperatively, and incision healing was observed. One month after surgery, the model was successfully established. This model simulates estrogen deficiency through surgical ovariectomy, requiring aseptic techniques throughout to minimize the risk of infection. During the experiment, appropriate animal handling was carried out in accordance with the "Guiding Opinions on the Ethical Treatment of Laboratory Animals" issued by the Department of Science and Technology of China.
[0078] 2.2 Micro-CT assessment of osteoporosis in mice
[0079] After the osteoporosis model was successfully established, the above-mentioned materials were injected into the tail vein for treatment every three days for one month. After the treatment, a Micro-CT scanning system (model: Skyscan 1276, Bruker) was used to quantitatively evaluate the bone mass and microstructural parameters of the distal femur of the mice. After anesthesia, the mice were fixed in the scanning chamber, and the scanning parameters were set to 50kV, 200μA, and 9μm resolution. The scanning range was the distal femoral metaphysis, as shown in Figure 2. Figure 16 The three-dimensional trabecular structure was reconstructed using CTAn analysis software, and the bone volume fraction (BV / TV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp) and trabecular number (Tb.N) were calculated. Figure 17 .
[0080] Micro-CT scan images and statistical results showed that bone volume fraction (BV / TV), trabecular number (Tb.N), and mineral density (BMD) significantly increased in all treatment groups, while trabecular separation (Tb.Sp) significantly decreased, indicating that bone loss was effectively curbed. The fCA-BExo composite treatment group showed the most significant reduction in bone loss.
[0081] 2.3 Mouse femur specimen collection, fixation, decalcification, and embedding procedures
[0082] After micro-CT scanning, mice were sacrificed, and bilateral femurs were completely dissected and the surrounding soft tissue removed. Specimens were fixed in 4% paraformaldehyde (pH 7.4) for 24 hours and then transferred to 10% EDTA decalcifying solution (containing 0.1% sodium azide) for 4 weeks at 4°C (with the solution changed every 48 hours). Complete decalcification was confirmed by needle puncture. After dehydration, specimens were cleared with graded ethanol and xylene, immersed in paraffin (60°C), and embedded in paraffin blocks. Serial coronal sections, each 5 μm thick, were prepared.
[0083] 2.4 HE staining
[0084] Paraffin sections were dewaxed with xylene and hydrated with graded ethanol. They were then stained with hematoxylin for 5 minutes, differentiated with 1% hydrochloric acid and ethanol for 30 seconds, and then blued with running water for 10 minutes. They were then stained with eosin for 2 minutes, dehydrated with graded ethanol, transparentized with xylene, and mounted with neutral gum. The trabecular structure and bone marrow cavity morphology were observed under a light microscope, and the bone tissue area ratio was analyzed using ImageJ software. Figure 18 , scale bar is 100 μm.
[0085] The experimental results showed that the trabeculae at the femoral epiphysis of mice in the OVX group were sparse and broken, the bone marrow cavity expanded significantly, and the proportion of bone tissue area was significantly reduced; while the trabecular structure of the fCA-BExo treatment group was significantly restored, the bone matrix was arranged tightly and continuously, and the proportion of bone tissue area was higher than that of the OVX group and close to the level of the sham operation group.
[0086] TRAP staining
[0087] A TRAP staining kit was used. After dewaxing and hydration, sections were incubated with tartrate-containing naphthol AS-BI phosphate substrate and Fast Red TR colorant at 37°C for 1 hour in the dark. Cell nuclei were counterstained with hematoxylin. The number of TRAP-positive multinucleated osteoclasts (≥3 nuclei) on the bone surface was counted under a light microscope. Bone resorption activity was quantified as the number of osteoclasts per millimeter of bone circumference. Figure 19 , scale bar is 100 μm.
[0088] Quantitative analysis of TRAP staining showed a significant increase in the number of TRAP-positive multinucleated osteoclasts on the bone surface in the OVX group, suggesting that estrogen deficiency leads to enhanced bone resorption. In contrast, the number of osteoclasts in the fCA-BExo-treated group was significantly reduced compared with the OVX group, with reduced cell size and nuclear fragmentation. These results are consistent with the improvements in micro-CT bone mass parameters, suggesting that fCA-BExo may mitigate bone loss by inhibiting osteoclast differentiation or activity.
[0089] 2.6 Safranin Fast Green Staining
[0090] Based on the cartilage-bone matrix differential staining method, sections were dewaxed and hydrated, stained with 0.1% Fast Green FCF for 5 minutes, differentiated with 1% acetic acid for 10 seconds, and stained with 0.1% Safranin O solution for 30 minutes. The sections were dehydrated with graded ethanol and mounted. Cartilage tissue appeared red, and bone matrix appeared green. The structural integrity of the junction between subchondral bone and calcified cartilage was assessed under a Nikon microscope. Figure 20 , scale bar is 100 μm.
[0091] Staining revealed that the subchondral bone and calcified cartilage interface in the OVX group was structurally disrupted, with thinning of the cartilage layer and decreased Safranin O staining intensity, suggesting cartilage matrix degradation. In contrast, the fCA-BExo group showed improved subchondral bone plate continuity, increased Safranin O staining intensity in the calcified cartilage region, and uniform distribution of Fast Green-stained bone matrix. These results suggest that fCA-Exo may delay osteoporosis progression by protecting the microstructural integrity of the cartilage-bone interface.
[0092] 2.7 Masson staining
[0093] The trichrome staining method was used to show the distribution of collagen in bone tissue. The sections were stained with Weigert iron hematoxylin for 5 minutes, stained with a mixture of ponceau red and acid fuchsin for 10 minutes, differentiated with 1% phosphomolybdic acid for 3 minutes, and counterstained with aniline blue for 5 minutes. Bone collagen fibers appear blue, while muscle fibers and cytoplasm appear red. The density of collagen fibers between trabeculae and the proportion of mineralized areas were analyzed. Figure 21 , scale bar is 100 μm.
[0094] Masson staining revealed loose and disordered collagen fibers between trabeculae in the OVX group, a decreased proportion of blue collagen, and a blurred boundary between mineralized and non-mineralized areas. In the fCA-BExo-treated group, collagen fibers were densely arranged and orderly, with a similar proportion of blue collagen as in the sham-surgery group, and a clearly visible mineralization front. Combined with Micro-CT bone density data, this suggests that fCA-BExo promotes collagen matrix deposition and enhances bone mineralization efficiency, thereby improving bone biomechanical properties.
Claims
1. A fCA-BExo nano-exosome complex material, characterized in that: It includes cobalt-aluminum layered double hydroxide and exosomes located on its surface.
2. The fCA-BExo nano-exosome complex material according to claim 1, characterized in that The exosomes are produced by co-culturing cobalt-aluminum layered double hydroxide and stem cells.
3. The fCA-BExo nano-exosome complex material according to claim 1, characterized in that The preparation method of the cobalt-aluminum layered double hydroxide is as follows: a cobalt-based substrate and an aluminum-based substrate are heated and stirred under the action of an activating agent, formamide, to form the cobalt-aluminum layered double hydroxide.
4. A method for preparing the fCA-BExo nanosheet-exosome composite material according to any one of claims 1 to 3, characterized in that: The following steps are involved: (1) Dissolve 218.275 mg of cobalt nitrate hexahydrate in 20 ml of deionized water to form a red solution, which is Solution A. At the same time, dissolve 93.783 mg of aluminum nitrate nonahydrate in 20 ml of deionized water to obtain a transparent solution, which is Solution B. Under stirring conditions, Solution A and Solution B are simultaneously added dropwise to 20 ml of 23% formamide solution preheated to 85°C over 10 minutes, and the pH value of the reaction system is maintained at 10 throughout the reaction. After the reaction is completed, the precipitate is collected by centrifugation and washed to obtain f-CA(OH) nanosheets; (2) Bone marrow mesenchymal stem cells were cultured at a rate of 5×10 6 Cells were seeded at a density of 100 cells / mL in a culture flask. When the cells reached approximately 60% confluency, complete culture medium containing 0.1 mg / mL f-CA(OH) nanosheets was added for 24 hours. The culture medium was then replaced with serum-free medium containing the same concentration of f-CA(OH) and incubated for another 24 hours. The culture supernatant was collected and centrifuged, and the resulting precipitate was resuspended in PBS to obtain fCA-BExo.
5. Use of the fCA-BExo nanosheet-exosome composite material according to any one of claims 1 to 3 as a ROS scavenging material and osteogenic induction material.
